Introduction
Globally an estimated 370,000 children are newly infected with HIV-1 each year, the majority as a result of mother-to-child transmission(1). Infants born to HIV-1-infected mothers consume large volumes of breastmilk containing HIV-1, but despite this exposure ~80% of these breastfeeding infants remain uninfected (2) . It is possible that these infants escape infection due to natural resistance, either through genetics, innate immunity, or acquired immunity, which protects them from acquiring HIV-1.
The discovery of HIV-1-specific cellular immune responses in individuals exposed to HIV-1 but who remain uninfected (EU) has been of particular interest as adaptive immunity may protect against acquisition of infection. Among HIV-1-infected adults, HIV-1-specific cellular immune responses are associated with control of viral replication and viral clearance (3, 4) and slower HIV-1 disease progression (5) (6) (7) (8) (9) (10) (11) . In the pre-antiretroviral era, waning of these responses correlated with disease progression (12) (13) (14) . HIV-1-specific cellular immune responses have been reported in varied HIV-1 EU populations, including commercial sex workers (15) (16) (17) , HIV-1-discordant couples (18) (19) (20) , and infants born to HIV-1-infected women (21) (22) (23) . CD4
+ and CD8 + HIV-1-specific responses have been observed in EU infants, with prevalence ranging from 3-56% (24) (25) (26) (27) and 0-47% (22, (27) (28) (29) (30) (31) , respectively, resulting in controversy around the detection of these responses and their potential protective role. However, vaccine development relies on understanding the induction of immune responses, and so it remains important to identify the correlates of presence and magnitude of HIV-1-specific immune responses in EU individuals.
Historic cohorts of infants of HIV-1-infected mothers who breastfeed offer a natural human challenge study because they are continuously exposed to HIV-1 from their mothers. With both viral source and recipient identifiable, mother-infant cohorts provide a unique opportunity to investigate correlates of infant cellular immune responses.
We hypothesized that factors associated with exposure to increased levels of HIV-1 antigen would increase induction of HIV-1-specific immune responses. To test our hypothesis, we compared the prevalence, magnitude, and breadth of infant HIV-1-specific T cell responses between breastfeeding HIV-1 EU infants born to women randomized to short-course zidovudine/nevirapine (ZDV/NVP) or highly active antiretroviral therapy (HAART)
[ZDV/lamivudine (3TC)/NVP], both shown to impact the levels of HIV-1 cell-free virus exposure in breastfeeding infants. Additionally, we examined maternal systemic and breastmilk HIV-1 viral levels as correlates of infant HIV-1-specific responses. advised to stop breastfeeding 6 months after delivery, and women in the HAART arm were advised to discontinue taking HAART after breastfeeding cessation.
Materials and Methods

Study
Maternal blood specimens were collected at 32 weeks gestation, within 2 days of delivery, then 2 weeks, 1 month, and every 3 months after delivery for HIV-1 RNA levels.
Breastmilk was obtained 1-3 times per week for the first month, then 3 and 6 months postpartum for breastmilk cell-free HIV-1 RNA and cell-associated HIV-1 DNA levels. Blood samples collected from infants at delivery and then at 1, 3, 6, 9, and 12 months of age were used to determine HIV-1 infection status and for enzyme-linked immunospot (ELISpot) assays.
Laboratory Methods
The processing of breastmilk specimens has been described elsewhere (34) . Briefly, breastmilk samples were separated into supernatant and cells after discarding the lipid layer.
Plasma and breastmilk HIV-1 RNA levels were determined using the Gen-Probe HIV-1 viral load assay (Gen-Probe Inc., USA), as previously described (34, 35) , with a lower limit of detection of 200 copies/ml and 100 copies/ml for plasma and breastmilk samples, respectively. Infant filter paper blood specimens were tested to determine HIV-1 status by HIV-1 DNA PCR (36) . HIV-1 DNA from breastmilk cells was extracted using the QIAmp DNA mini kit (Qiagen, USA) and quantified using real-time PCR as previously described (33, 34) . The lower limit of detection was 1 copy/reaction, and HIV-1 DNA levels were normalized to the number of cells tested (number of β-actin copies). CD4 counts were measured from blood samples using flow cytometry variable. Magnitude of responses was defined as the summed magnitude of HIV-1-specific SFU/10 6 PBMC across all peptide pools.
Viral loads below the limit of detection were recoded to the mid-point between zero and the limit of detection for that assay. Because a high percentage (55%) of breastmilk HIV-1 RNA assays were below the limit of detection, breastmilk HIV-1 RNA was modeled as a dichotomized covariate (detected/not detected). Infant HIV-1-specific IFN-γ responses were compared between the two randomization groups at each visit. ELISpot prevalence was compared using
Pearson's Chi-squared tests or Fisher's exact tests, and magnitude and breadth of responses were compared using Mann-Whitney U tests. Linear regression was used to assess correlates of magnitude of ELISpot HIV-1-specific responses (background subtracted) in all infants at specific time points. Generalized estimating equation (GEE) models with a Poisson link and exchangeable correlation structure were used to examine associations between maternal viral load and infant ELISpot responses over time. All regression models were adjusted for treatment arm and constructed with robust standard errors. Sensitivity analyses were performed in which samples with undetectable HIV-1 DNA levels and fewer than 10,000 cells tested were excluded from regression models. Stata version 11.2 (College Station, USA) was used for all analyses.
Results
Study population and characteristics
Of 60 mother-infant pairs, 3 infants acquired HIV-1 during follow-up and were excluded from the ELISpot analyses; 47 (78%) infants had ELISpot data at ≥1 visit. Among the selected mother-infant pairs, median age and CD4 cell count at 32 weeks gestation did not differ between trial arms (Table 1) . While plasma HIV-1 RNA levels were similar between the two groups at 32 weeks gestation, women randomized to ZDV/NVP had significantly higher plasma viral loads (~2 log 10 copies/ml higher) from delivery to 6 months postpartum compared to women randomized to HAART (33) . (Table 3A) . Thus for every log 10 increase in viral load during gestation, infants had ~600/10 6 additional HIV-specific cells in circulation by one month of life. In contrast for every log 10 increase in breastmilk HIV-1 DNA month 1 postpartum, there was a 0.54 (95% CI=0.11-0.97, p=0.02) log 10 increase in magnitude of infant IFN-γ responses (Table 3A) . Thus for every log 10 increase in concurrent breastmilk viral load, 
Discussion
In this study, prevalence and correlates of HIV-1-specific IFN-γ responses among breastfeeding HIV-1-exposed uninfected (EU) infants born to mothers on antiretroviral therapy were evaluated. We found 45% of infants were able to generate cellular immune responses of substantial breadth and magnitude; however, most responses were transient. Our finding confirms previous studies that detected responses in HIV-1 EU infants (22, 27, 28, 31) and is consistent with our previous study that observed 47% prevalence of at least one positive ELISpot assay using HLA-matched peptide stimulation in breastfeeding EU infants(29). We also found significant associations between maternal plasma and breastmilk HIV-1 viral levels and infant magnitude of HIV-1-specific ELISpot responses, suggesting that antigen exposure modifies the induced infant HIV-1-specific immune responses.
In contrast to our study hypothesis, we did not observe that randomization to the ZDV/NVP arm was associated with higher infant HIV-1-specific immune responses. We may have been underpowered to detect a difference between the two arms, however, the absence of a difference by treatment is consistent with our finding that breastmilk cell-associated HIV-1 DNA predicted infant IFN-γ responses. We previously demonstrated in this cohort that whereas breastmilk cell-free virus was significantly decreased in women on HAART, breastmilk cellassociated virus (as measured by HIV-1 DNA levels) remained similar to women in the ZDV/NVP arm (34) , and the persistence of breastmilk HIV-1 DNA despite HAART has also been observed in a study from Botswana(37). Thus, although breastfeeding infants born to mothers on HAART had less exposure to maternal cell-free virus, there was persistent exposure to HIV-1 infected cells in breastmilk, and this may be a key determinant in generating infant immune responses.
We found a significant association between maternal pregnancy plasma HIV-1 RNA We observed infant ELISpot responses that were of relatively high magnitude and were comparable to levels noted after HIV-1 vaccines in trials among adults (43) (44) (45) . Responses were detected in 3 infants at 1 month of age, suggesting responses can be primed very early in life;
however, these responses were not maintained and subsequently disappeared in all 3 infants.
The characteristics of these infant responses are analogous to what may be expected among recipients of a prime-boost vaccine (46) . The lack of persistent immune responses in infants suggests that initial in utero priming of responses may not be sufficient for a sustained response, perhaps due to antiretroviral treatment decreasing maternal HIV-1 viral load in the last trimester. As for route of vaccine delivery, our data and others (19, 38) 
